abstract：:This phase I study was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) with standard doses of cisplatin and etoposide for patients with untreated, extensive-stage small cell lung cancer. Secondary objectives were to determine the toxicities, response ...

journal_title：Seminars in oncology

authors： Bunn PA Jr,Kelly K

更新日期：1997-08-01 00:00:00

abstract：:The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation t...

journal_title：Seminars in oncology

authors： Rosenthal DI,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Greiner J,Frenkel EF,Carbone DP

更新日期：1997-08-01 00:00:00

abstract：:In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung ca...

journal_title：Seminars in oncology

authors： Pisters KM,Kris MG,Bunn PA Jr,Johnson DH,Ruckdeschel JC,Crowley JJ,Ginsberg RJ

更新日期：1997-08-01 00:00:00

abstract：:Lung cancer represents the leading cause of cancer mortality worldwide. Its incidence has declined in men but is increasing in women, assuring that this largely preventable disease will continue to affect millions. In small cell lung cancer, the advent of chemotherapy in the 1970s and continued refinements in the 1980...

journal_title：Seminars in oncology

authors： Splinter TA

更新日期：1997-08-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the United States. Lung cancer is frequently encountered by the radiologist, whether the lung cancer is detected on a chest radiograph obtained in a symptomatic patient, or is an incidental finding. The radiologic workup of pulmonary lesions suspected of being lung c...

journal_title：Seminars in oncology

authors： Broderick LS,Tarver RD,Conces DJ Jr

更新日期：1997-08-01 00:00:00

abstract：:This article reviews the associations of cancer with rheumatic diseases. Recent epidemiologic data linking the autoimmune connective tissue diseases with malignancy will be emphasized. Reports linking the occurrence of malignancy with rheumatoid arthritis, systemic lupus erythematosus, idiopathic inflammatory myopathy...

journal_title：Seminars in oncology

authors： Carsons S

更新日期：1997-06-01 00:00:00

abstract：:Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

journal_title：Seminars in oncology

authors： Pestka S

更新日期：1997-06-01 00:00:00

abstract：:This randomized, multinational, multicenter study was designed to determine the response rate of gemcitabine monotherapy and cisplatin/etoposide combination therapy in chemotherapy-naive patients with advanced, recurrent, and/or metastatic non-small cell lung cancer (stage IIIA [if inoperable], IIIB, or IV). One group...

journal_title：Seminars in oncology

authors： Manegold C,Drings P,von Pawel J,Ricci S,Dornoff W,van Walree N,ten Bokkel Huinink W,Chemaissani A,Stahel P,Bergman B,Wagenius G,Sederholm C,Mattson K,Liippo K,Kellokumpu-Lehtinen P

更新日期：1997-06-01 00:00:00

abstract：:We studied the efficacy of endoscopic variceal ligation (EVL) in 16 patients with tumor thrombus of the portal vein trunk (Vp3) associated with hepatocellular carcinoma. The average (+/-SD) number of O rings used was 9.0 +/- 5.0 for the esophageal varices (n = 7) and 16.4 +/- 4.5 for the esophagogastric varices (n = 9...

journal_title：Seminars in oncology

authors： Kokubu S,Matsumoto Y,Murakami M,Shibata H,Saigenji K

更新日期：1997-04-01 00:00:00

abstract：:Combination therapy consisting of Lipiodol (Laboratoire Guerbet, Villepinte, France) containing styrene maleic acid neocarzinostatin and transcatheter arterial embolization (L-TAE) has been an important conservative therapy for hepatocellular carcinoma (HCC). We examined the clinical and pathologic characteristics of ...

journal_title：Seminars in oncology

authors： Kenji J,Hyodo I,Tanimizu M,Tanada M,Nishikawa Y,Hosokawa Y,Mandai K,Moriwaki S

更新日期：1997-04-01 00:00:00

abstract：:We resected 158 cases of hepatocellular carcinoma (HCC), including 20 (12.6%) cases of large HCC. These 20 cases were divided into group 1 (curative resection, n = 9) and group 2 (noncurative resection, n = 11). The clinicopathologic features and long-term survival of the cases were evaluated. In groups 1 and 2, porta...

journal_title：Seminars in oncology

authors： Noguchi T,Kawarada Y,Kitagawa M,Ito F,Sakurai H,Machishi H,Yamagiwa K,Yokoi H,Mizumoto R

更新日期：1997-04-01 00:00:00

abstract：:Compelling data implicate angiogenesis and tumor-associated neovascularization as a central pathogenic step in the process of tumor growth, invasion, and metastasis. These complex processes involve multiple steps and pathways dependent on the local balance between positive and negative regulatory factors, as well as i...

journal_title：Seminars in oncology

authors： Pluda JM

更新日期：1997-04-01 00:00:00

abstract：:Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the s...

journal_title：Seminars in oncology

authors： Le Chevalier T,Gottfried M

更新日期：1997-04-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) appears to be one of the most active drugs in the treatment of advanced head and neck cancer. The maximum tolerated dose of paclitaxel in combination with carboplatin is currently being evaluated in phase I/II studies. We designed a phase II study to eval...

journal_title：Seminars in oncology

authors： Fountzilas G,Athanassiadis A,Samantas E,Skarlos D,Kalogera-Fountzila A,Nikolaou A,Bacoyiannis H,Stathopoulos G,Kosmidis P,Daniilidis J

更新日期：1997-02-01 00:00:00

abstract：:Recently, a randomized study conducted by the Gynecologic Oncology Group (GOG 111) demonstrated that, given by a 24-hour infusion, the combination of cisplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is superior to combination cisplatin/cyclophosphamide in previously untreated patients with...

journal_title：Seminars in oncology

authors： Meerpohl HG,du Bois A,Luck HJ,Kühnle H,Möbus V,Kreienberg R,Bauknecht T,Köchli O,Bochtler H,Diergarten K

更新日期：1997-02-01 00:00:00

abstract：:Tamoxifen has been demonstrated to be hepatocarcinogenic in some but not all strains of the laboratory rat and is not a carcinogen in the mouse. To resolve the question of whether tamoxifen is genotoxic in humans, many laboratories have studied its interspecies metabolism and its propensity to form DNA adducts. This r...

journal_title：Seminars in oncology

authors： Tannenbaum SR

更新日期：1997-02-01 00:00:00

abstract：:The epidemiologic studies relevant to the hypothesis that exposure to tamoxifen is associated with risk of cancer of the endometrium and perhaps other organs are described, summarized, and evaluated. One large body of data comes from the randomized trials of tamoxifen as a therapeutic agent against established breast ...

journal_title：Seminars in oncology

authors： MacMahon B

更新日期：1997-02-01 00:00:00

abstract：:Patients with acute myeloid leukemia and acute lymphocytic leukemia receive significant numbers of blood products for hematologic support during periods of disease and treatment related cytopenias. These patients may be at increased risk for complications associated with transfusion. This article reviews the indicatio...

journal_title：Seminars in oncology

authors： Webb IJ,Anderson KC

更新日期：1997-02-01 00:00:00

abstract：:Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting...

journal_title：Seminars in oncology

authors： Saltz L,Janik JE

更新日期：1997-02-01 00:00:00

abstract：:Predicting which patients with primary melanoma are at risk of developing metastastic disease is important for making rational therapeutic decisions. Tumor thickness alone is the most commonly used predictor of survival, but other clinical and pathologic variables also play an important role. We have developed two mul...

journal_title：Seminars in oncology

authors： Halpern AC,Schuchter LM

更新日期：1997-02-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally thought of as relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M p...

journal_title：Seminars in oncology

authors： Glantz MJ,Choy H,Akerley W,Kearns CM,Egorin MJ,Rhodes CH,Cole BF

更新日期：1996-12-01 00:00:00

abstract：:This phase I dose-escalation study was undertaken to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and ifosfamide that could be administered without growth factors to previously untreated patients with non-small cell lung cancer. Forty patients with advanced n...

journal_title：Seminars in oncology

authors： Shepherd FA,Latreille J,Paul K,Eisenhauer E

更新日期：1996-12-01 00:00:00

abstract：:In studies conducted by the Eastern Cooperative Oncology Group, treatment with either paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) or carboplatin was associated with an improvement in 1-year survival in patients with stage IV non-small cell lung cancer (NSCLC). Based on these findings, a phase II tr...

journal_title：Seminars in oncology

authors： Johnson DH,Paul DM,Hande KR,DeVore R

更新日期：1996-12-01 00:00:00

abstract：:Most malignant melanomas in the ocular region arise in the uveal tract (iris, ciliary body, and choroid). Uveal melanoma generally has characteristic clinical features and the diagnosis can usually be made by an experienced ophthalmologist using slit lamp biomicroscopy or indirect ophthalmoscopy. Ancillary studies suc...

journal_title：Seminars in oncology

authors： Shields JA,Shields CL,De Potter P,Singh AD

更新日期：1996-12-01 00:00:00

abstract：:Evidence is reviewed separating unusual variants of melanoma from the large group of superficial spreading and nodular (SSM/NOD) histogenetic types. These include (1) the relationship of moles to melanoma of the SSM/ NOD types not found in melanoma arising in lentigo maligna (LMM), desmoplastic neurotrophic melanoma (...

journal_title：Seminars in oncology

authors： Sagebiel RW

更新日期：1996-12-01 00:00:00

abstract：:Despite marked improvements in the treatment options available for patients with lung cancers, more than 85% of patients ultimately relapse and die of their disease. Among the most auspicious of new agents available to treat lung cancers, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) also has been th...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1996-12-01 00:00:00

abstract：:The management of metastatic prostate cancer that has relapsed after initial hormonal manipulation remains a major problem, with the majority of patients dying within 12 months. Their clinical course is frequently characterized by progressive debilitation, pain, and other tumor-related symptoms. A phase II, non-random...

journal_title：Seminars in oncology

authors： Raghavan D,Coorey G,Rosen M,Page J,Farebrother T

更新日期：1996-12-01 00:00:00

abstract：:Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant eto...

journal_title：Seminars in oncology

authors： Budman DR

更新日期：1996-12-01 00:00:00

abstract：:This phase I trial was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin (400 mg/m2) as first-line chemotherapy for stage IIIC/IV ovarian adenocarcinoma. After premedication, paclitaxel was infu...

journal_title：Seminars in oncology

authors： Lhommé C,Kerbrat P,Lejeune C,Guastalla JP,Fumoleau P,Goupil A,Héron JF,Cassin MA,Pruvot I,Soares JA,Chazard M

更新日期：1996-10-01 00:00:00

abstract：:Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria for an effective combination include use of drugs with different mechanisms of action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; B...

journal_title：Seminars in oncology

authors： Holmes FA

更新日期：1996-10-01 00:00:00

abstract：:Gemcitabine, a novel nucleoside analog, shows reproducible response rates of 20% and above in single-agent studies in non-small cell lung cancer. In the phase II studies reported, chemotherapy-naive patients received gemcitabine (starting doses, 800 to 1,250 mg/ m2) as a single agent on days 1, 8, and 15 of a 28-day c...

journal_title：Seminars in oncology

authors： Le Chevalier T

更新日期：1996-10-01 00:00:00

abstract：:Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (Ie, Ta, Tl, and carcinoma in situ [CIS]) with specific objectives that include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression, and prolonging s...

journal_title：Seminars in oncology

authors： Nseyo UO,Lamm DL

更新日期：1996-10-01 00:00:00

abstract：:The ability to predict the biological behavior of breast tumors can allow selection of the optimum treatment and follow-up strategies. Conventionally, tumor size, lymph node metastases, and histopathologic features have been used to determine the risk of systemic relapse. The discovery of a number of specific genetic ...

journal_title：Seminars in oncology

authors： Dhingra K,Hortobagyi GN

更新日期：1996-08-01 00:00:00

abstract：:Selective aromatase inhibitors cause regression of breast carcinomas by reducing estrogen production via inhibition of the enzyme aromatase (estrogen synthetase). A higher incidence of hormone-dependent breast cancer occurs in postmenopausal women than in younger women. Thus, total estrogen blockade is more likely to ...

journal_title：Seminars in oncology

authors： Brodie AM,Njar VC

更新日期：1996-08-01 00:00:00

abstract：:The treatment of locally advanced carcinoma of the cervix with radiation therapy as a single modality is inadequate, specifically for stage III and IVA disease. While chemotherapy as single-modality therapy is ineffective in advanced cervical cancer, there is some evidence of efficacy when used in combination with rad...

journal_title：Seminars in oncology

authors： Wadler S,Goldberg G,Fields A,Anderson P,Beitler JJ,Sood B,Haynes H,Runowicz C

更新日期：1996-08-01 00:00:00

abstract：:Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients. At the Institut Gustave-Roussy, we performed a phase II study of high-dose ifosfamide without...

journal_title：Seminars in oncology

authors： Tursz T

更新日期：1996-06-01 00:00:00

abstract：:Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated. In response to these limitations, other single agents have been studied, and a number have demonstr...

journal_title：Seminars in oncology

authors： Roth BJ

更新日期：1996-06-01 00:00:00

abstract：:Present status of gastric cancer surgery in Japan and several new procedures are reviewed in this article. Japanese treatment results of this disease were significantly better than Western results even when stages were adjusted. Generally speaking, Japanese surgical procedures are more aggressive and meticulous compar...

journal_title：Seminars in oncology

authors： Maruyama K,Sasako M,Kinoshita T,Sano T,Katai H

更新日期：1996-06-01 00:00:00

abstract：:Pancreatic cancer is one of the most lethal neoplasms. Incidence in the United States has remained fairly stable over the past 25 years, with about 25,000 cases annually. Almost 100% of cases are fatal. Incidence in the developed world parallels that in the United States. Incidence in undeveloped nations is lower but ...

journal_title：Seminars in oncology

authors： Ahlgren JD

更新日期：1996-04-01 00:00:00

abstract：:Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid, and ifosfamide have each shown activity as a single agent and in various combination-chemotherapy regimens against non-small cell lung cancer. Vinorelbine usually has been...

journal_title：Seminars in oncology

authors： Masters GA,Hoffman PC,Drinkard LC,Watson S,Samuels BL,Golomb HM,Vokes EE

更新日期：1996-04-01 00:00:00